The Health Sciences Innovation and Entrepreneurship (HSIE) Training Program has been awarded a $952,975 grant over five years to continue its pioneering work teaching postdoctoral fellows at UAMS how to commercialize their discoveries.
AR Health Ventures Accelerator proudly announces its inaugural cohort, funding innovative projects in biofilm inhibition, radiation-responsive cancer therapy, and advanced liver injury detection, marking a significant leap in medical research.
Empowering Arkansas entrepreneurs in healthcare and health tech. Receive comprehensive support and networking opportunities to accelerate your venture. Apply now to join the 2024 cohort and shape the future of healthcare entrepreneurship. Visit bioventures.tech/active to learn more and apply today!
BioVentures has announced a licensing agreement with Harmonic Discovery and UC San Francisco for the development of a new drug
Submit your proposals for the AR Health Ventures Accelerator program by September 29th. Apply now!
As part of the TRI Research Fundamentals Seminar Series. Dr. Kennon-McGill will be sharing her insights on “Intellectual Property, Innovation, and Commercialization”.
BioVentures strengthens strategic direction at AUTM 2023, bolstering industry connections and insights to propel technology transfer endeavors.
Are you a biomedical entrepreneur or small business in need of resources to accelerate your innovation? If the answer is yes, you’re in luck! The National Institute of Health (NIH), Arkansas Small Business and Technology Development Center (ASBTDC), University of Arkansas for Medical Sciences (UAMS), and BioVentures are collaborating to bring you a one-of-a-kind event titled “Supporting Biomedical Innovation Through the NIH SBIR/STTR Programs”. This event is tailored to help biomedical entrepreneurs and small businesses uncover early-stage funding opportunities and gain insights from the success stories of local startups. With over $1.4 billion of funding available through the NIH’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, there is a wealth of opportunities to explore. What to Expect: The event kicks off with an overview of resources provided by the ASBTDC. This will provide attendees with a comprehensive understanding of what support is available to them locally. Next, expect to hear from NIH Program Staff from the NHLBI, the National Institute of Dental and Craniofacial Research, and the NCI. They’ll delve into the specifics of the NIH’s SBIR and STTR programs, highlighting the available funding opportunities and entrepreneurial resources that could be a game-changer for your small business. Attendees will also gain exclusive insights from Dr. Alex Biris and Ms. Sharon Ballard, the dynamic cofounders of the local startup NuShores Biosciences. They’ll share their personal experiences with the NIH SBIR program and the journey of bringing their innovative ideas to life. Once the presentations are concluded, you’ll have a chance to clarify any doubts during a Q&A session moderated by Catherine Corley, an ASBTDC Business and Innovation Consultant. This interaction promises to be a great opportunity to get your questions answered directly from the experts. One-on-one meetings with NIH Program Staff will be available post-event. This offers you a personalized opportunity to discuss your innovative ideas and explore potential funding avenues. Key Details: “Supporting Biomedical Innovation Through the NIH SBIR/STTR Programs” is set to be a pivotal moment for biomedical entrepreneurs and small businesses in Arkansas. Don’t miss out on this unique opportunity to connect with the NIH, gain valuable insights into the SBIR/STTR programs, and accelerate your biomedical innovation. Mark your calendar, register now, and get ready to take your business to new heights! We look forward to seeing you there!
Discover the exciting investment opportunities below, offered by leading life science companies: GlaxoSmithKline (GSK) Collaborations The director of Academic Alliances at GSK is willing to evaluate researchers and their departments for collaboration in their specific areas of interest. They are willing to put dollars behind people and expect collaboration. GSK can even offer their clinical services. Net result: GSK will typically provide $1-4M and ask for exclusivity/options on a pre-negotiated basis! If an Opportunity exists, BioVentures can bridge discussions with the GSK team! Medtronic Investment Opportunities The business development team evaluates the opportunity according to the surgical area. The respective team will review the opportunity presented in a one-page executive briefing. After vetting, they bring in the “New Venture Development” arm. They expect the researcher to form a spin-out company and continue the ongoing work through investment dollars. The Medtronic BD team expects a one-pager to encompass the following: Net Result: Medtronic can invest in startups anywhere between $500K and $5M. Pathway to Cures Pathway-to-Cures is the venture arm of the National Hemophilia Foundation. Pathway-to-Cures invests in blood disorders and oncology; however, they will examine other therapeutic areas. Net Result: As a non-profit, they are willing to invest $100K to assist a researcher in establishing proof-of-concept; as a university spinout company, they are ready to invest between $500K and $1,000,000. J&J Innovations Investments across pharmaceuticals, medical devices, and consumer healthcare Partner with Bio Ventures to access J&J Innovations funding and explore investment opportunities in a wide range of healthcare sectors. If you are a researcher interested in pursuing collaborations with industry partners or seeking funding opportunities, BioVentures is here to help. Our team of experts can provide guidance and connect you with the right people at these companies. It is important to carefully evaluate any potential partnerships or funding opportunities and ensure they align with your research goals and values. Contact BioVentures today to unlock the investment potential of your research: bioventures@uams.edu
